Teva Pharmaceutical Industries Ltd (ADR)  

(Public, NYSE:TEVA)   Watch this stock  
Find more results for Barr Pharmaceuticals, Inc.�
+1.35 (2.38%)
Dec 19 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 56.54 - 58.61
52 week 38.97 - 58.87
Open 57.00
Vol / Avg. 6.05M/3.98M
Mkt cap 54.03B
P/E 18.04
Div/yield 0.32/2.34
EPS 3.21
Shares 956.39M
Beta 0.64
Inst. own 54%
Feb 4, 2015
Q4 2014 Teva Pharmaceutical Industries Ltd Earnings Release (Estimated) - 7:00AM EST - Add to calendar
Dec 11, 2014
Teva Pharmaceutical Industries Ltd 2015 Business Outlook - Webcast
Oct 30, 2014
Q3 2014 Teva Pharmaceutical Industries Ltd Earnings Call - Webcast
Oct 30, 2014
Q3 2014 Teva Pharmaceutical Industries Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 17.16% 6.37%
Operating margin 21.98% 8.12%
EBITD margin - 27.58%
Return on average assets 7.46% 2.64%
Return on average equity 14.90% 5.60%
Employees 44,945 -
CDP Score - 73 D


5 Basel St., P.O. Box 3190
+972-3-9267267 (Phone)
+972-3-9234050 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva�s active pharmaceutical ingredient (API) business provides vertical integration to Teva�s own pharmaceutical production. The Company�s global operations are conducted from North and Latin America to Europe and Asia. Teva operates a number of subsidiaries in such countries as Canada, Croatia, the Czech Republic, France, Germany, Hungary, Ireland, Israel, Japan, Poland, the Russian Federation, Spain, the Netherlands, the United Kingdom and the United States. In February 2014, the Company's subsidiary, Train Merger Sub, Inc, fully acquired NuPathe Inc. In July 2014, it acquired Labrys.

Officers and directors

Phillip Frost M.D. Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Erez Vigodman President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Robert Koremans M.D. President, Chief Executive Officer-Global Specialty Medicines
Age: 52
Bio & Compensation  - Reuters
Amir Elstein Vice Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Eyal Desheh Group Executive Vice President, Chief Financial Officer President
Age: 61
Bio & Compensation  - Reuters
Kobi Altman Senior Vice President, CFO Americas and Head of Finance Operations
Age: 45
Bio & Compensation  - Reuters
Dipankar Bhattacharjee Senior Vice President, CFO Americas and Head of Finance Operations
Age: 53
Bio & Compensation  - Reuters
Carlo De Notaristefani Ph.D. President and Chief Executive Officer, Global Operations
Age: 56
Bio & Compensation  - Reuters
Itzhak Krinsky Chairman, Teva Japan and Teva South Korea, Head - Business Development Asia-Pacific
Age: 61
Bio & Compensation  - Reuters
Allan Oberman President and Chief Executive Officer of Teva Americas Generics
Age: 56
Bio & Compensation  - Reuters